TREatment of degeNerative and Neoplastic Diseases With Rituximab

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
This is a prospective international, multi-center, randomized, double-blind controlled study designed to assess and compare the pharmacokinetics, pharmacodynamics and the safety of PBO-326 (Rituximab) and Mabthera (Rituximab) in combination with CHOP in previously untreated patients with diffuse B cells Non Hodgkin lymphoma.
Epistemonikos ID: 52b7a0682221ff5aae74a27c4bb596e58e45a79e
First added on: May 06, 2024